Q2 2016 results - Unilabs delivers 8th consecutive quarter of organic sales and EBITDA growth
Q2 results delivered increased organic growth in net sales of 4.2% CER (1.8% reported) and organic EBITDA growth up by 20.1% CER (17.3% reported) on a like for like basis. The combination of constant revenue growth and excellent results from the Cost Leadership Initiative contributed to the substantial growth of EBITDA margins. The 2016 guidance is confirmed.
Skaraborgs Hospital puts its trust in Unilabs again
Skaraborgs Hospital has chosen to extend the existing laboratory services agreement with Unilabs in Sweden. The agreement covers the complete laboratory medical service for clinical chemistry, microbiology, pathology, cytology and transfusion medicine.
The three years extension applies from February 2020.

Our Partnerships, Expertise & Network

We are a partner of choice and leading provider of outsourced diagnostic services with more than 200 diagnostic contracts across Europe.
Our services include: laboratory medicine, medical imaging, histopathology, reproductive medicine, and drug development services.
With operations in 12 countries, we are positioned as a regional leader with one of the broadest geographic coverage in Europe.